Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin

Prostate

Volumn 73, Issue 9, 2013, Pages 970-978

  Gee, Jason ^a,f   Bailey, Howard ^a   Kim, Kyungmann ^a   Kolesar, Jill ^a   Havighurst, Tom ^a   Tutsch, Kendra D ^a   See, William ^b   Cohen, Michael B ^c   Street, Nick ^d   Levan, Leon ^e   Jarrard, David ^a   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d Department of Management Sciences ^*  (United States)

^e Bone Care International   (United States)

^f LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

chemoprevention; prostate cancer; vitamin D

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; DOXERCALCIFEROL; FIBROBLAST GROWTH FACTOR; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN; VITAMIN D; VITAMIN D RECEPTOR;

ADULT; ARTICLE; CAPILLARY DENSITY; CHILL; CONTROLLED STUDY; COUGHING; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPOPHOSPHATEMIA; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; THROMBOCYTE; VITAMIN SUPPLEMENTATION;

ENDPOINT DETERMINATION; ERGOCALCIFEROLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; KALLIKREINS; MALE; MICROVESSELS; MIDDLE AGED; PLACEBOS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN D;

EID: 84878317552     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22644     Document Type: Article

References (32)

1. Siegel R, Naishadham MA, Jemal A,. Cancer Statistics, 2012. CA Cancer J Clin 2012; 62 (1): 10-29.
2. Brawley OW, Barnes S, Parnes H,. The future of prostate cancer prevention. Ann NY Acad Sci 2001; 952: 145-152.
3. Davidson D, Bostwick DG, Qian J, Wollan PC, Oesterling JE, Rudders RA, Siroky M, Stilmant M,. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: Predictive accuracy in needle biopsies. J Urol 1995; 154: 1295-1299.
4. Ahn J, Moslehi R, Weinstein SJ, Snyder K, Virtamo J, Albanes D,. Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Cancer 2008; 123 (5): 1154-1159.
5. Lieberman R,. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials. Urology 2001; 57 (4 Suppl 1) 224-229.
6. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-224.
7. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362 (13): 1192-1202.
8. Schwartz GG, Hulka BS,. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 1990; 10: 1307-1311.
9. Schwartz GG, Wang MH, Zhang M, Singh RK, Siegal GP,. 1 alpha, 25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomark Prev 1997; 6: 727-732.
10. Corder EH, Friedman GD, Vogelman JH, Orentreich N,. Seasonal variation in vitamin D, vitamin D binding protein, and dehydroepiandrosterone: Risk of prostate cancer in black and white men. Cancer Epidemiol Biomark Prev 1995; 4: 655-659.
11. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P,. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000; 11 (9): 847-852.
12. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M,. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004; 108 (1): 104-108.
13. DeLuca HF, Zierold C,. Mechanisms and functions of vitamin D. Nutr Rev 1998; 56 (2 pt 2): S4-S10.
14. Lin R, White JH,. The pleiotropic actions of vitamin D. Bioessays 2004; 26 (1): 21-28.
15. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB,. Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Serum vitamin D concentration and prostate cancer risk: A nested case-control study. J Natl Cancer Inst 2008; 100 (11): 796-804.
16. Hedlund TE, Moffatt KA, Miller GJ,. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: Evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinol 1996; 1317: 1554-1561.
17. Miller GH, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P,. Human prostate carcinoma cell line LNCaP expresses biologically active specific receptors for 1α25 dihydroxyvitamin D3. Cancer Res 1992; 52: 515-520.
18. Feldman D,. Androgen and vitamin D receptor gene polymorphisms: The long and short of prostate cancer risks. J Natl Cancer Inst 1997; 89: 109-111.
19. Ingles SA, Ross RK, Yu MC, Irvine RA, LaPera G, Haile RW, Coetzee GA,. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 166-170.
20. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA,. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996; 56: 4108-4110.
21. Marks R, Foley PA, Jolley D, Knight KR, Harrison J, Thompson SC,. The effect of regular sunscreen use on vitamin D levels in an Australian population. Arch Dermatol 1995; 131: 415-421.
22. Skowronski RJ, Peehl DM, Feldman D,. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinol 1993; 132: 1952-1960.
23. Skowronski RJ, Peehl DM, Feldman D,. Actions of vitamin D3 analogs on human prostate cancer cell lines: Comparison with 1,25 dihydroxyvitamin D3. Endocrinol 1995; 136: 20-26.
24. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WC,. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98 (7): 451-459.
25. Lissner D, Mason RS, Posen S,. Stability of vitamin D metabolites in human blood serum and plasma. Clin Chem 1981; 27 (5): 773-774.
26. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM,. Associations of demographic and lifestyle characteristics with prostate specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006; 106 (2): 320-328.
27. Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, Liu G,. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res 2008; 14 (8): 2437-2443.
28. Vecino-Vecino C, Gratton M, Kremer R, Rodriguez-Mañas L, Duque G,. Seasonal variance in serum levels of vitamin d determines a compensatory response by parathyroid hormone: Study in an ambulatory elderly population in Quebec. Gerontology 2006; 52 (1): 33-39.
29. Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF,. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol 2005; 202 (2): 361-370.
30. Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR, Gudkov AV,. Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 2004; 101 (18): 7112-7117.
31. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H,. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004; 64 (23): 8715-8722.
32. Vesalainen S, Lipponen P, Talja M, Kasurinen J, Syrjänen K,. Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas. Prostate 1995; 27: 110-117.